DR. DENNIS J SELKOE, MD
Neurology in Boston, MA
License number
Massachusetts 37223
Category
Neurology
Type
Neurology
Address
Address
77 Ave, Boston, MA 02115
Phone
(617) 525-5200
(617) 525-5252 (Fax)
(617) 724-0287
(617) 726-2894 (Fax)
(617) 525-5252 (Fax)
(617) 724-0287
(617) 726-2894 (Fax)
Professional information
Dr. Dennis J Selkoe, Boston MA - MD (Doctor of Medicine)
Specialties:
Neurology, Neuropsychiatry (Neurology)
Address:
Brigham Behavioral Neurology
221 Longwood Ave STE M80, Boston 02115
(617) 732-8060 (Phone)
221 Longwood Ave STE M80, Boston 02115
(617) 732-8060 (Phone)
Certifications:
Neurology, 1977
Awards:
Healthgrades Honor Roll
Languages:
English, German
Hospitals:
Brigham Behavioral Neurology
221 Longwood Ave STE M80, Boston 02115
Brigham and Women's Hospital
75 Francis St, Boston 02115
221 Longwood Ave STE M80, Boston 02115
Brigham and Women's Hospital
75 Francis St, Boston 02115
Education:
Medical School
Virginia Commonwealth University School Of Medicine
Graduated: 1969
Hospital Of The University Of Pennsylvania
Graduated: 1970
Pb Brigham/Chldns Hosp/Beth
Graduated: 1975
Chldns Hospital Med Center
Graduated: 1978
Virginia Commonwealth University School Of Medicine
Graduated: 1969
Hospital Of The University Of Pennsylvania
Graduated: 1970
Pb Brigham/Chldns Hosp/Beth
Graduated: 1975
Chldns Hospital Med Center
Graduated: 1978
Screening Compounds For The Ability To Alter The Production Of Amyloid- Peptide
US Patent:
6610493, Aug 26, 2003
Filed:
Jun 18, 1996
Appl. No.:
08/665649
Inventors:
Martin Citron - Thousands Oaks CA
Dennis J. Selkoe - Jamaica Plain MA
Peter A. Seubert - San Francisco CA
Dale Schenk - Burlingame CA
Dennis J. Selkoe - Jamaica Plain MA
Peter A. Seubert - San Francisco CA
Dale Schenk - Burlingame CA
Assignee:
Brigham and Womens Hospital - Boston MA
Athena Neurosciences, Inc. - South San Francisco CA
Athena Neurosciences, Inc. - South San Francisco CA
International Classification:
G01N 3353
US Classification:
435 71, 435 72, 435 721, 435 723, 435 78, 435 792
Abstract:
This invention provides methods of screening compounds for their ability to alter the production of A(x 41) alone or in combination with A(x40). The methods involve administering compounds to cells, specifically measuring the amounts of A(x40) and A(x 41) produced by the cells, and comparing these amounts to that produced by the cells without administration of the compounds.
Methods For Determining Whether A Compound Alters The Amount Of At Least One Αβ (X-41) Peptide And The Amount Of Either Total Αβ Or At Least One Αβ (X-40) Peptide Produced By A Non-Human Mammal
US Patent:
7993627, Aug 9, 2011
Filed:
Dec 30, 2002
Appl. No.:
10/335035
Inventors:
Martin Citron - Thousand Oaks CA, US
Dennis J. Selkoe - Jamaica Plain MA, US
Peter A. Seubert - San Francisco CA, US
Dale B. Schenk - Burlingame CA, US
Dennis J. Selkoe - Jamaica Plain MA, US
Peter A. Seubert - San Francisco CA, US
Dale B. Schenk - Burlingame CA, US
Assignee:
Elan Pharmaceuticals, Inc. - South San Francisco CA
Brigham and Women's Hospital - Boston MA
Brigham and Women's Hospital - Boston MA
International Classification:
A61K 49/00
US Classification:
424 91, 800 3, 435 71
Abstract:
This invention provides methods of screening compounds for their ability to alter the production of Aβ(x≧41) alone or in combination with Aβ(x≦40). The methods involve administering compounds to cells, specifically measuring the amounts of Aβ(x≦40) and Aβ(x≧41) produced by the cells, and comparing these amounts to that produced by the cells without administration of the compounds.
Diagnostic Method For Alzheimer's Disease: Examination Of Non-Neural Tissue
US Patent:
5262332, Nov 16, 1993
Filed:
Sep 19, 1989
Appl. No.:
7/410138
Inventors:
Dennis J. Selkoe - Jamaica Plain MA
Assignee:
Brigham and Women's Hospital - Boston MA
International Classification:
G01N 3353, G01N 33543
US Classification:
436518
Abstract:
This invention provides a method as well as a kit for diagnosing Alzheimer's disease. The method comprises the steps of obtaining a non-neural tissue biopsy sample, contacting at least a portion of the sample with a quantity of antibodies capable of identifying. beta. AP, a. beta. -amyloid precursor protein fragment comprising. beta. AP, or a. beta. AP peptide fragment of about 8 or more amino acids sufficient to allow detection of said protein, protein fragment or peptide fragment, and monitoring the extent of the reaction between the sample and the antibodies. The kit comprises antibodies specific for. beta. -amyloid protein, or a. beta. -amyloid precursor protein fragment comprising. beta. -amyloid protein, or a peptide fragment of. beta. -amyloid protein of at least about eight amino acids, and a means for detecting the extent of the reaction of the antibodies with a non-neural tissue sample.
Methods And Compositions For The Detection Of Soluble .Beta.-Amyloid Peptide
US Patent:
5837672, Nov 17, 1998
Filed:
Jun 1, 1995
Appl. No.:
8/456347
Inventors:
Dale B. Schenk - Pacifica CA
Michael G. Schlossmacher - Vienna, AT
Dennis J. Selkoe - Jamaica Plain MA
Peter A. Seubert - South San Francisco CA
Michael G. Schlossmacher - Vienna, AT
Dennis J. Selkoe - Jamaica Plain MA
Peter A. Seubert - South San Francisco CA
Assignee:
Athena Neurosciences, Inc. - So. San Francisco CA
Eli Lilly and Company - Indianapolis IN
Brigham and Women's Hospital - Boston MA
Eli Lilly and Company - Indianapolis IN
Brigham and Women's Hospital - Boston MA
International Classification:
A61K 3100, A61K 3800
US Classification:
514 2
Abstract:
Soluble. beta. -amyloid peptide (. beta. AP) is measured in biological fluids at very low concentrations, typically in the range from 0. 1 ng/ml to 10 ng/ml. The measurement of. beta. AP concentrations in animals or conditioned medium from cultured cells can be used for drug screening, where test compounds are administered to the animals or exposed to the cultured cells and the accumulation of. beta. AP in the animal or culture medium observed. It has been found that elevated levels of. beta. AP in body fluids, such as blood and cerebrospinal fluid, is associated with the presence of a. beta. AP-related condition in a patient, such as Alzheimer's Disease. Methods for diagnosing and monitoring. beta. AP-related conditions comprise measuring the levels of. beta. AP in such body fluids from a patient.
Methods Of Screening For Compounds Which Inhibit Soluble .Beta.-Amyloid Peptide Production
US Patent:
5766846, Jun 16, 1998
Filed:
Jun 17, 1993
Appl. No.:
8/079511
Inventors:
Michael G. Schlossmacher - Vienna, AT
Dennis J. Selkoe - Jamaica Plain MA
Dennis J. Selkoe - Jamaica Plain MA
Assignee:
Athena Neurosciences - South San Francisco CA
Eli Lilly and Company - Indianapolis IN
Eli Lilly and Company - Indianapolis IN
International Classification:
G01N 3353
US Classification:
435 6
Abstract:
Soluble. beta. -amyloid peptide (. beta. AP) is measured in biological fluids at very low concentrations, typically in the range from 0. 1 ng/ml to 10 ng/ml. The measurement of. beta. AP concentrations in animals or conditioned medium from cultured cells can be used for drug screening, where test compounds are administered to the animals or exposed to the cultured cells and the accumulation of. beta. AP in the animal or culture medium observed. It has been found that elevated levels of. beta. AP in body fluids, such as blood and cerebrospinal fluid, is associated with the presence of a. beta. AP-related condition in a patient, such as Alzheimer's Disease. Methods for diagnosing and monitoring. beta. AP-related conditions comprise measuring the levels of. beta. AP in such body fluids from a patient.
Method For Identifying .Beta.-Amyloid Peptide Production Inhibitors
US Patent:
6284221, Sep 4, 2001
Filed:
Oct 18, 1996
Appl. No.:
8/733202
Inventors:
Dale B. Schenk - Pacifica CA
Michael G. Schlossmacher - Vienna, AU
Dennis J. Selkoe - Jamaica Plain MA
Peter A. Seubert - South San Francisco CA
Michael G. Schlossmacher - Vienna, AU
Dennis J. Selkoe - Jamaica Plain MA
Peter A. Seubert - South San Francisco CA
Assignee:
Elan Pharmaceuticals, Inc. - South San Francisco CA
Eli Lilly and Company - Indianapolis IN
Brigham and Women's Hospital, Inc. - Boston MA
Eli Lilly and Company - Indianapolis IN
Brigham and Women's Hospital, Inc. - Boston MA
International Classification:
A61K 4900, A01K 67027
US Classification:
424 92
Abstract:
A method for identifying inhibitors of the production of. beta. -amyloid peptides by administration of a compound to a mammalian host is provided.
Tetrameric Alpha-Synuclein As Biomarkers
US Patent:
2013030, Nov 21, 2013
Filed:
Nov 4, 2011
Appl. No.:
13/883550
Inventors:
Dagmar Ringe - Cambridge MA, US
Gregory A. Petsko - Belmont MA, US
Dennis J. Selkoe - Boston MA, US
Tim Bartels - Brookline MA, US
Gregory A. Petsko - Belmont MA, US
Dennis J. Selkoe - Boston MA, US
Tim Bartels - Brookline MA, US
Assignee:
THE BRIGHAM AND WOMEN'S HOSPITAL, INC. - Boston MA
BRANDEIS UNIVERSITY - Waltham MA
BRANDEIS UNIVERSITY - Waltham MA
International Classification:
G01N 33/68
US Classification:
435 72
Abstract:
The present invention provides the surprising finding that alpha-synuclein exists in vivo as a folded tetramer. Provided are various methods and technologies that arise from this finding, including methods and kits for identifying individuals susceptible to or suffering from certain diseases, disorders or conditions associated with stability of alpha-synuclein tetramers, and/or individuals likely (or not) to respond to therapy with agents that alter level and/or stability of alpha-synuclein tetramers.
Sulfonamide-Containing Compounds
US Patent:
2013031, Nov 21, 2013
Filed:
Oct 4, 2011
Appl. No.:
13/877419
Inventors:
Corinne E. Augelli-Szafran - Newton MA, US
Dai Lu - Boston MA, US
Hanxun Wei - West Roxbury MA, US
Jing Zhang - Lexington MA, US
Michael S. Wolfe - Newton MA, US
Dennis J. Selkoe - Jamaica Plain MA, US
Dai Lu - Boston MA, US
Hanxun Wei - West Roxbury MA, US
Jing Zhang - Lexington MA, US
Michael S. Wolfe - Newton MA, US
Dennis J. Selkoe - Jamaica Plain MA, US
Assignee:
THE BRIGHAM AND WOMEN'S HOSPITAL, INC. - Boston MA
International Classification:
C07C 311/16, C07C 311/18, C07D 295/32, C07D 263/14, C07D 213/42, C07C 311/19, C07D 271/06
US Classification:
5142388, 564 92, 514604, 548131, 514364, 548238, 514374, 546338, 514357, 544159
Abstract:
This invention relates generally to the discovery of sulfonamide-containing compounds that are inhibitors of γ-secretase.
Tetrameric Alpha-Synuclein And Use Thereof
US Patent:
2013028, Oct 31, 2013
Filed:
Nov 4, 2011
Appl. No.:
13/883552
Inventors:
Dagmar Ringe - Cambridge MA, US
Gregory A. Petsko - Belmont MA, US
Dennis J. Selkoe - Boston MA, US
Tim Bartels - Brookline MA, US
Gregory A. Petsko - Belmont MA, US
Dennis J. Selkoe - Boston MA, US
Tim Bartels - Brookline MA, US
Assignee:
BRANDEIS UNIVERSITY - Waltham MA
International Classification:
G01N 33/68, A61K 45/00, C07K 16/18
US Classification:
514221, 506 11, 5303879, 5303873
Abstract:
Disclosed herein are methods and related compositions for identifying compounds that stabilize natively folded tetrameric α-synuclein. These methods and compositions are useful for the treatment and diagnosis of α-synuclein-associated diseases and disorders.